Clinical Trial Update: Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Roxadustat to reduce the incidence of acute kidney injury after coronary artery bypass grafting was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Roxadustat (roxadustat)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Coronary Artery Bypass | Phase 2 | Status: TERMINATED